NCT05226494View on ClinicalTrials.gov

Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 23, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Glioma, Malignant
Interventions
DRUG

fb-PMT

Daily dosing based on patient weight

Trial Locations (1)

06511

RECRUITING

Smilow Cancer Hospital, New Haven

Sponsors
All Listed Sponsors
lead

NanoPharmaceuticals LLC

INDUSTRY

NCT05226494 - Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter